Sökning: WFRF:(Hamalainen Heikki) >
Plasma soluble Urok...
Plasma soluble Urokinase-Type Plasminogen activator receptor is not associated with neurological Outcome in Patients with aneurysmal subarachnoid hemorrhage
-
- Kiiski, Heikki (författare)
- Tampere Univ Hosp, Dept Intens Care, Crit Care Med Res Grp, Tampere, Finland.
-
- Jalkanen, Ville (författare)
- Tampere Univ Hosp, Dept Intens Care, Crit Care Med Res Grp, Tampere, Finland.
-
- Ala-Peijari, Marika (författare)
- Tampere Univ Hosp, Dept Intens Care, Crit Care Med Res Grp, Tampere, Finland.
-
visa fler...
-
- Hamalainen, Mari (författare)
- Univ Tampere, Tampere Univ Hosp, Fac Med & Life Sci, Immunopharmacol Res Grp, Tampere, Finland.
-
- Moilanen, Eeva (författare)
- Univ Tampere, Tampere Univ Hosp, Fac Med & Life Sci, Immunopharmacol Res Grp, Tampere, Finland.
-
- Peltola, Jukka (författare)
- Univ Tampere, Tampere Univ Hosp, Dept Neurol, Tampere, Finland.
-
- Tenhunen, Jyrki (författare)
- Uppsala universitet,Anestesiologi och intensivvård,Tampere Univ Hosp, Dept Intens Care, Crit Care Med Res Grp, Tampere, Finland.
-
visa färre...
-
Tampere Univ Hosp, Dept Intens Care, Crit Care Med Res Grp, Tampere, Finland Univ Tampere, Tampere Univ Hosp, Fac Med & Life Sci, Immunopharmacol Res Grp, Tampere, Finland. (creator_code:org_t)
- 2017-04-18
- 2017
- Engelska.
-
Ingår i: Frontiers in Neurology. - : FRONTIERS MEDIA SA. - 1664-2295. ; 8
- Relaterad länk:
-
https://uu.diva-port... (primary) (Raw object)
-
visa fler...
-
https://doi.org/10.3...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- Object: Aneurysmal subarachnoid hemorrhage (aSAH) is a common cause of death or long-term disability. Despite advances in neurocritical care, there is still only a very limited ability to monitor the development of secondary brain injury or to predict neurological outcome after aSAH. Soluble urokinase-type plasminogen activator receptor (suPAR) has shown potential as a prognostic and as an inflammatory biomarker in a wide range of critical illnesses since it displays an association with overall immune system activation. This is the first time that suPAR has been evaluated as a prognostic biomarker in aSAH. Methods: In this prospective population-based study, plasma suPAR levels were measured in aSAH patients (n = 47) for up to 5 days. suPAR was measured at 0, 12, and 24 h after patient admission to the intensive care unit (ICU) and daily thereafter until he/ she was transferred from the ICU. The patients' neurological outcome was evaluated with the modified Rankin Scale (mRS) at 6 months after aSAH. Results: suPAR levels (n = 47) during the first 24 h after aSAH were comparable in groups with a favorable (mRS 0-2) or an unfavorable (mRS 3-6) outcome. suPAR levels during the first 24 h were not associated with the findings in the primary brain CT, with acute hydrocephalus, or with antimicrobial medication use during 5-days' follow-up. suPAR levels were associated with generally accepted inflammatory biomarkers (C-reactive protein, leukocyte count). Conclusion: Plasma suPAR level was not associated with either neurological outcome or selected clinical conditions. While suPAR is a promising biomarker for prognostication in several conditions requiring intensive care, it did not reveal any value as a prognostic biomarker after aSAH.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Anestesi och intensivvård (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Anesthesiology and Intensive Care (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- aneurysmal subarachnoid hemorrhage
- biomarkers
- neurological outcome
- secondary brain injury
- soluble urokinase-type plasminogen activator receptor
- neuroinflammation
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas